Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery
Tevogen Bio (Nasdaq: TVGN) announced that its Founder and CEO, Dr. Ryan Saadi, has donated 10,000 shares of his personal common stock to the Opportunity Project, a New Jersey-based nonprofit organization focused on brain injury recovery. The donation complies with SEC Rule 144, and Dr. Saadi will not receive any proceeds from the securities disposal.
The Opportunity Project, established in 1993, has supported over 600 individuals and their families through its Clubhouse model, promoting independence, self-esteem, and community reintegration for individuals with brain injuries.
Tevogen Bio (Nasdaq: TVGN) ha comunicato che il suo fondatore e CEO, il Dr. Ryan Saadi, ha donato 10.000 azioni del suo patrimonio personale di azioni ordinarie a The Opportunity Project, un'organizzazione no-profit del New Jersey dedicata al recupero dopo lesioni cerebrali. La cessione rispetta la Regola 144 della SEC e il Dr. Saadi non riceverà alcun ricavo dalla vendita di questi titoli.
Fondata nel 1993, The Opportunity Project ha sostenuto oltre 600 persone e le loro famiglie attraverso il suo modello Clubhouse, favorendo l'indipendenza, l'autostima e il reinserimento sociale delle persone con lesioni cerebrali.
Tevogen Bio (Nasdaq: TVGN) anunció que su fundador y CEO, el Dr. Ryan Saadi, donó 10.000 acciones de su capital personal de acciones comunes a The Opportunity Project, una organización sin fines de lucro de Nueva Jersey centrada en la recuperación de lesiones cerebrales. La donación cumple con la Regla 144 de la SEC y el Dr. Saadi no obtendrá ingresos por la disposición de estos valores.
Fundado en 1993, The Opportunity Project ha apoyado a más de 600 personas y sus familias mediante su modelo Clubhouse, fomentando la independencia, la autoestima y la reintegración comunitaria de quienes sufren lesiones cerebrales.
Tevogen Bio (Nasdaq: TVGN)는 창업자 겸 CEO인 Dr. Ryan Saadi가 개인 보유 보통주 10,000주를 뇌손상 회복을 지원하는 뉴저지 기반 비영리단체 The Opportunity Project에 기부했다고 발표했습니다. 이번 기부는 SEC 규칙 144을 준수하며, Dr. Saadi는 해당 증권 처분으로부터 어떠한 수익도 받지 않습니다.
1993년 설립된 The Opportunity Project는 Clubhouse 모델을 통해 600명 이상과 그 가족들을 지원해 왔으며, 뇌손상 환자들의 자립, 자존감 및 지역사회 재통합을 촉진하고 있습니다.
Tevogen Bio (Nasdaq: TVGN) a annoncé que son fondateur et PDG, le Dr Ryan Saadi, a fait don de 10 000 actions de ses actions ordinaires personnelles à The Opportunity Project, une association à but non lucratif du New Jersey dédiée à la récupération après des lésions cérébrales. Le don est conforme à la règle 144 de la SEC et le Dr Saadi ne percevra aucun produit issu de la cession de ces titres.
Créé en 1993, The Opportunity Project a accompagné plus de 600 personnes et leurs familles via son modèle Clubhouse, favorisant l'autonomie, l'estime de soi et la réinsertion communautaire des personnes ayant subi des lésions cérébrales.
Tevogen Bio (Nasdaq: TVGN) gab bekannt, dass sein Gründer und CEO, Dr. Ryan Saadi, 10.000 Aktien seines persönlichen Stammaktienbestands an The Opportunity Project, eine gemeinnützige Organisation aus New Jersey zur Unterstützung der Genesung nach Hirnverletzungen, gespendet hat. Die Zuwendung entspricht der SEC-Regel 144, und Dr. Saadi wird aus der Veräußerung der Wertpapiere keine Erlöse erhalten.
Das 1993 gegründete The Opportunity Project hat über 600 Personen und deren Familien durch sein Clubhouse-Modell unterstützt und fördert Unabhängigkeit, Selbstwertgefühl und die Wiedereingliederung in die Gemeinschaft von Menschen mit Hirnverletzungen.
- None.
- None.
WARREN, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that Founder and CEO of Tevogen, Dr. Ryan Saadi, donated 10,000 of his personal shares of common stock to the Opportunity Project, a Millburn, N.J.–based nonprofit dedicated to empowering individuals with brain injuries through its innovative Clubhouse model. Founded in 1993, Opportunity Project has served more than 600 individuals and their families, providing programs that foster independence, self‑esteem, and community reintegration.
“This donation is a small way to express my admiration for Opportunity Project’s work and its impact on so many lives,” said Dr. Saadi. “As a fellow New Jersey organization, we share a deep commitment to supporting our community and advancing human potential.”
The donation was conducted in accordance with SEC Rule 144 and Dr. Saadi will not receive any proceeds from the disposal of the securities.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
How many shares did Tevogen Bio's CEO donate to the Opportunity Project?
What is the Opportunity Project and who does it serve?
Will Tevogen Bio's CEO receive any proceeds from the share donation?
Where is Tevogen Bio (TVGN) headquartered?
